Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KDSTEM Inj. in Chronic Kidney Disease
NCT06071143Phase 1Completed
- Sponsor
- EHL Bio Co., Ltd.
- Start
- Feb 2024
- Primary completion
- Mar 2026
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KDSTEM inj in chronic kidney disease (CKD), sponsored by EHL Bio Co., Ltd. Primary endpoint: Number of subjects with treatment-related adverse events at 28 weeks. Started Feb 2024; status: completed.
02
Drugs
KDSTEM inj.
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT06071143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06071143.